Skip to content

Biosimilars Review & Report

Biosimilars, Biologics, FDA Policy and Approvals, Clinical Trials, and Specialty Pharmacy

Biosimilar Approval Status
Home
- Home
About BR&R
News and Commentary
BR&R Manufacturer Profiles
- Amneal Biosciences
- Samsung Bioepis
Contact Us

$0.00 0 items

Home / Products tagged “Biosimilar Industry Report 2021”

Biosimilar Industry Report 2021

Showing the single result

The US Biosimilar Market: A History of Growth and Towards a Sustainable Future
$99.95 Add to cart

Search for:

Recent Posts

100% Tariffs Slapped on Pharmaceutical Companies, With Many Exceptions: Circumventing the Supreme Court? April 3, 2026
FDA vs. EMA Biosimilar Approvals, an Update March 30, 2026
Samsung Bioepis, Sandoz Forge Deeper Biosimilar Ties March 19, 2026
As Oncology Biosimilar Acquisition Prices Fall for Hospitals, Biosimilar Adoption Rises March 16, 2026
The FDA’s New Draft Guidance Contributes to Streamlined Biosimilar Development March 12, 2026
Two Leaders’ Views on National PBM Reform: Biosimilar and ERISA Benefits March 9, 2026
Deeper Views on TrumpRx (the Direct-to-Patient Channel), MFN and MFP, and Biosimilars March 5, 2026
A Filgrastim Biosimilar Approval, and a Bevacizumab Rejection February 27, 2026
Will National PBM Reform Whither Away the Private-Label Channel? February 23, 2026
Navigating Biosimilar Substitution February 18, 2026

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Email Address

Recent Comments

	Drug Manufacturers’… on The Inflation Reduction Act: R…
	Drug Manufacturers’… on Thirty Years of Exclusivity fo…
	Manjiri Kulkarni on What is Cordavis and Why Will…
	MK on Where’s Pfizer’s Adalimumab Bi…
	Vinay Patel on The Adalimumab Biosimilar Grea…

Archives

Archives

Meta

Log in
Entries feed
Comments feed
WordPress.org

Top Posts & Pages

Samsung Bioepis Manufacturer Profile Page FINAL
The Evolution of the Biosimilars Market
100% Tariffs Slapped on Pharmaceutical Companies, With Many Exceptions: Circumventing the Supreme Court?
Celltrion Gains First Omalizumab Biosimilar Approval
Biosimilar Approval Status
Twelve Potential Competitors and Counting: An Update of the Denosumab Biosimilar Pipeline
Denosumab Biosimilar Competitors Gathering Data for February 2025 Launch
26/15/9: Biosimilars at the Crossroads
Amgen Launches Amjevita® With Two WAC-Based Pricing Options
A Conversation With Sarfaraz K. Niazi, PhD: Part 2

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.

To find out more, including how to control cookies, see here: Cookie Policy

Follow Us

X
LinkedIn

Home
About BR&R
Biosimilar Approval Status
Contact Us
Terms and Conditions
Privacy Policy

Copyright

Copyright 2013-2026 by SM Health Communications LLC. All Rights Reserved

Powered by WordPress.com.

Loading Comments...

Write a Comment...

Email (Required)

Name (Required)

Website